Nonetheless, as both (−)-epicatechin and CAT-SKL have been used therapeutically in mice11, 23, 24, pre-clinical research into the potential utility of combining an antioxidant with an anti-EGFR drug in treating breast cancer may be relatively straight forward. Here, EGFR is linked to breast cancer.